InvestorsHub Logo
Followers 8
Posts 443
Boards Moderated 0
Alias Born 03/25/2016

Re: None

Tuesday, 08/18/2020 9:15:05 AM

Tuesday, August 18, 2020 9:15:05 AM

Post# of 233532
mTNBC Abstract just published
https://cancerres.aacrjournals.org/content/80/16_Supplement/CT233

Conclusion: "Conclusions: Leronlimab (PRO 140), a CCR5 antagonist mAb, in combination with carboplatin is currently enrolling newly diagnosed mTNBC. The preliminary analysis shows safety and tolerability of the combination and continue to enroll patients with initial promising clinical activity, potentially suggesting the future availability of a new effective agent in the management of this serious condition."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News